Clinical Trial

Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 15, 2023 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg/day or clopidogrel 75 mg/day) with or without a combination of antioxidants (N-acetylcysteine 600 mg/day) in a dry AMD patient with large drusen. Participants will divided in to three groups. * Participants who were already taking low dose antiplatelet medications. * Participants who take the antiplatelet drug mentioned above in addition to the antioxidant prescribed by the investigator * Participants does not use any medications.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-01.
Trial Details
NCT Number NCT06165068
Lead Sponsor Navamindradhiraj University
Conditions Dry Age-related Macular Degeneration
Enrollment 174 participants
Start Date 2023-12
Primary Completion 2025-12 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2023-12-15